MoFo News Item

Morrison & Foerster wins exceptional fee award for client Genentech in Kadcyla patent row

16 Aug 2018

California federal Judge Beth Freeman ruled in favor of firm client Genentech on Monday, granting attorneys’ fees in a long-winding patent infringement case brought by Phigenix against the blockbuster breast cancer drug Kadcyla. In the ruling, Judge Freeman also agreed to join Dr. Carlton Donald, the inventor of the patent at issue, to the case and to allow Genentech to refile its motion to assess fees against him directly.

Phigenix first brought the case against Genentech in 2014 and Judge Freeman dismissed the suit on summary judgment in August 2017, finding no induced infringement. MoFo attorneys argued for exceptional case fees in March 2018.

The MoFo team on the case was led by Michael Jacobs and included Catherine Polizzi, Matthew Kreeger, Matthew Chivvis, Jamie Kendall, Chanwoo Park, Sorin Zaharia, Yan Qi, and Chris Meier. The firm is also currently representing Genentech on Phigenix’s appeal of its defeat to the Federal Circuit.  The case is Phigenix Inc. v. Genentech Inc., case number 5:15-cv-01238 (subscription required), in the U.S. District Court for the Northern District of California.



Unsolicited e-mails and information sent to Morrison & Foerster will not be considered confidential, may be disclosed to others pursuant to our Privacy Policy, may not receive a response, and do not create an attorney-client relationship with Morrison & Foerster. If you are not already a client of Morrison & Foerster, do not include any confidential information in this message. Also, please note that our attorneys do not seek to practice law in any jurisdiction in which they are not properly authorized to do so.